GSK plc (GSK) boasts a diversified base and presence in different geographical areas. The spin-off of the Consumer unit in 2022 has allowed it to focus on drug development. In July 2022, GSK de-merged its Consumer Healthcare segment into a standalone company. The independent Consumer Healthcare company was named Haleon (HLN) . Haleon was a consumer health joint venture, an over-the-counter medicines business, jointly created by GSK and partner Pfizer (PFE) in 2019. GSK has been regularly selling its stake i ...

WATERTOWN, Mass. and GOSSELIES, Belgium, July 08, 2024 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS) ("iTeos"), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of immuno-oncology therapeutics for patients, today announced the dosing of the first patient in GALAXIES Lung-301, a global, randomized, double-blind Phase 3 registrational clinical trial of belrestotug + dostarlimab versus placebo + pembrolizumab in patients with firstline advanc ...

Jemperli is currently approved for use in combination with standard-of-care chemotherapy combination, carboplatin and paclitaxel for treating adult patients with primary advanced or recurrent endometrial cancer that is either mismatch repair deficient or microsatellite instability-high in Europe. Shares of GSK have rallied 9.2% so far this year against the industry's decline of 5.8%. Jemperli is a key drug that aids GSK's oncology sales. The drug generated sales worth £80 million in the first quarter of 202 ...

Loading... Cantor projects around $1.1 billion of 5-year projected royalty revenues from GSK and initiates Innoviva with an Overweight rating. The company plans to expand Innoviva Specialty Therapeutics' product portfolio through organic and inorganic growth opportunities. Zoliflodacin could achieve over $500 million of annual peak sales in the U.S. Price Action: INVA shares are up 1.61% at $16.42 at last check Tuesday. Cantor Fitzgerald has initiated coverage on Innoviva, Inc. INVA, citing the company's un ...

GSK (GSK) announced that the FDA has approved the expanded use of its respiratory syncytial virus (RSV) vaccine, Arexvy for adults aged 50-59 who are at increased risk of RSV disease. Arexvy is currently approved in the United States, Europe, Japan and several other countries in adults aged 60 and more for the prevention of lower respiratory tract disease (LRTD) caused by RSV. With the latest approval, Arexvy becomes the first RSV vaccine approved for adults aged 50-59 who are at high risk. In the United St ...

The Food and Drug Administration on Friday expanded the approval of GSK's respiratory syncytial virus vaccine to adults ages 50 to 59 who are at increased risk of getting severely sick from the potentially lethal virus. The shot, called Arexvy, is the first vaccine cleared by the FDA to protect that population from RSV. The agency first approved GSK's jab in May 2023 for patients 60 and above, who are more vulnerable to severe cases of the virus. RSV causes thousands of hospitalizations and deaths among sen ...

Many investors expected today's move in GlaxoSmithKline (NYSE:GSK), with shares of GSK stock plunging more than 8% in early afternoon trading. That's because, on Friday, a Delaware judge ruled that expert witnesses would be allowed to testify in court that the company's discontinued Zantac heartburn medication may have caused cancer. This ruling will allow 70,000 lawsuits to proceed, alleging that Zantac caused cancer. Many investors in the U.K.-based drugmaker hoped the courts would dismiss this request, b ...

GSK (GSK) issued a statement disagreeing with the ruling by a state court in Delaware to allow jury trials for cases, which claim GSK's discontinued heartburn drug Zantac (ranitidine) causes cancer. The court's decision will allow 72,000 personal injury lawsuits filed in Delaware court to move forward to trial and expert witnesses to testify in court that Zantac may cause cancer. GSK shares declined more than 7% in pre-market trading on Monday in response to the legal setback. If the claims are proved in co ...

Company logo of pharmaceutical company GlaxoSmithKline is seen at their Stevenage facility, Britain October 26, 2020. LONDON — Shares of British pharmaceuticals giant GSK plunged 9% Monday, after a U.S. court ruled that scientific evidence could be presented in a stack of lawsuits relating to the discontinued heartburn drug Zantac. The Delaware State Court late on Friday ruled that plaintiffs' expert witnesses could testify in the roughly 75,000 cases alleging the once-popular drug ranitidine — sold under t ...

Guido Mieth GSK plc (NYSE:GSK), (OTCPK:GLAXF) is one of the largest pharmaceutical companies in Europe, with one of the leading positions in global markets for HIV drugs, and it also has an extensive portfolio of FDA-approved vaccines. Investment thesis Since the beginning of 2024, the company's share price has increased by more than 22% and continues to trade well above the 200 EMA, reflecting the optimism of financial market participants about GSK's business prospects even despite the impact of some of th ...